Videos

Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone-Sensitive Prostate Cancer

10/30/2025

Scott Tagawa, MD, Weill Cornell Medicine, New York, New York, discusses results from the phase 3 PSMAddition trial evaluating the addition of [177Lu]Lu-PSMA-617 (¹⁷⁷Lu-PSMA-617) to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) therapy for patients with metastatic hormone-sensitive prostate cancer.

This addition provided a statistically significant improvement in radiographic progression-free survival with consistent and manageable safety. These results support the potential of earlier use of radioligand therapy as part of combination treatment for advanced prostate cancer.

These results were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.

Source:

Tagawa S, Sartor O, Piulats JM, et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA6

© 2025 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Advancing Oncology Through Radiopharmaceutical Science and Innovation

The Radiopharmaceutical Education Institute (RPEI) will bridge the gap between research, clinical application, and patient care by delivering accessible, multidisciplinary expert insights and education on radiopharmaceuticals in oncology to our engaged national audience of oncologists, oncology advanced practitioners, oncology nurses, diagnostic radiologists, and nuclear medicine specialists.

The Oncology Learning Network and RPEI are also the official digital platforms for our Great Debates & Updates: Solid Tumor live meeting.

Insights from the ESMO Congress

Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone-Sensitive Prostate Cancer

Source:

© 2025 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Advancing Oncology Through Radiopharmaceutical Science and Innovation

HMP Global Products

Events